Injectable opportunities for CMOs despite internal capacity of big pharma sponsors
An increasing number of companies are turning to outsourcing to meet market demand for huge numbers of injectables.
By
Comment
Latest in
Comment
There is a large pipeline of CAR-T cell therapies for diffuse large B-cell lymphoma
Chimeric antigen receptor T (CAR-T) cells are a form of ACT in which cells are engineered to express a synthetic…
By
The potential of virtual reality-based therapy for serious mental disorders
Virtual reality (VR) technologies that can enhance recovery without anti-psychotics are an attractive option for treating mental illnesses.
By
Alnylam identifies gene to lower abdominal fat and decrease cardiovascular risk
Alnylam aims to develop a therapy that targets the INHBE gene and reduces the overall risk of T2D and coronary…
ByIncrease in dry powder inhalers could lead to decreases in greenhouse gas emissions
As dry powder inhalers are breath controlled, no propellant is used, making their carbon footprint significantly lower than that of…
By
UK health data collaboration paves the way to study long Covid symptoms
The University of Birmingham's long Covid study is one of the success stories exploring the global potential of data-driven healthcare,…
FDA approves Coherus’ Cimerli for DME, with year-long interchangeability exclusivity
Cimerli’s status as a biosimilar of Lucentis is appealing to DME treatment providers and patients alike in the US.
By
Tapping into pharma’s growing opportunities in digital health
Gérard Klop and Marcos Gallego Llorente of Vintura, explore how companies can grow their sphere of influence in the healthcare…